ProMIS Neurosciences, Inc. (PMN)

NASDAQ: PMN · IEX Real-Time Price · USD
1.910
-0.050 (-2.55%)
At close: Mar 28, 2024, 3:07 PM
1.860
-0.050 (-2.62%)
After-hours: Mar 28, 2024, 6:04 PM EDT
-2.55%
Market Cap 33.05M
Revenue (ttm) n/a
Net Income (ttm) -16.90M
Shares Out 18.89M
EPS (ttm) -1.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,899
Open 1.900
Previous Close 1.960
Day's Range 1.750 - 1.950
52-Week Range 0.950 - 8.950
Beta 0.69
Analysts Strong Buy
Price Target 8.00 (+318.85%)
Earnings Date May 13, 2024

About PMN

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and se... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PMN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PMN stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(318.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's Disease Adds Key U.S. and International Patent Allow...

17 days ago - GlobeNewsWire

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeut...

5 weeks ago - GlobeNewsWire

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodies Lead vaccine candidate selected for advan...

2 months ago - GlobeNewsWire

ProMIS Neurosciences Issues Letter to Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focus...

2 months ago - GlobeNewsWire

ProMIS Neurosciences, Inc. Announces Leadership Transition

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer

3 months ago - GlobeNewsWire

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degenera...

3 months ago - GlobeNewsWire

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study Advances novel monoclonal antibody designed to be highly selective f...

4 months ago - GlobeNewsWire

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Raised $20.4 million in PIPE gross proceeds to support continued development of Company's PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases

4 months ago - GlobeNewsWire

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond At-the-Market fundraise to support Company through several potentially value-creating milest...

7 months ago - GlobeNewsWire

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...

7 months ago - GlobeNewsWire

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neuros...

7 months ago - GlobeNewsWire

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Presented c ompelling preclinical data support ing therapeutic potential of PMN310 to treat Alzheimer's disease , and the promise of disease prevention with a computationally derived A lzheimer's dise...

8 months ago - GlobeNewsWire

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 17, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development o...

9 months ago - GlobeNewsWire

ProMIS Announces Completion of Continuance

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the “Corporation”) is pleased to announce that it has...

9 months ago - GlobeNewsWire

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development o...

9 months ago - GlobeNewsWire

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company focused on the generation and development...

9 months ago - GlobeNewsWire

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ ProMIS ” or the “Corporation”) is issuing this release to cor...

9 months ago - GlobeNewsWire

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

TORONTO, Ontario and CAMBRIDGE, Massachusetts , May 15, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development o...

11 months ago - GlobeNewsWire

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

11 months ago - GlobeNewsWire

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 25, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development ...

1 year ago - GlobeNewsWire

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development ...

1 year ago - GlobeNewsWire

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development ...

1 year ago - GlobeNewsWire

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for toxic oligomers indicates a poten...

1 year ago - GlobeNewsWire

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development ...

1 year ago - GlobeNewsWire

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development ...

1 year ago - GlobeNewsWire